E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome.
Zhang, Zi-Teng, Du, Xiu-Ming, Ma, Xiu-Juan et al. · Journal of neuroinflammation · 2016 · DOI
Quick Summary
Researchers created a mouse model of fatigue by exposing mice to immune stress (a bacterial compound) combined with physical stress. They found that a specific immune protein called NLRP3 becomes active in the brain during fatigue, and that blocking this protein reduced fatigue symptoms. This suggests that controlling this immune pathway might help treat fatigue in conditions like ME/CFS.
Why It Matters
This study identifies a potential molecular mechanism linking immune activation to fatigue sensation in the brain, specifically implicating the NLRP3 inflammasome pathway. For ME/CFS patients, this work provides a rationale for investigating NLRP3 or IL-1β-targeted therapies and strengthens the biological basis for understanding fatigue as an immune-mediated symptom.
Observed Findings
- Mice treated with LPS and swim stress showed decreased locomotor activity and reduced motor endurance compared to untreated controls.
- Serum IL-1β and IL-6 levels were elevated in treated mice.
- NLRP3 expression, IL-1β production, and caspase-1 activation were increased in the diencephalon of treated mice.
- NLRP3 knockout mice exhibited significantly increased locomotor activity and longer motor endurance after LPS and swim stress exposure.
- IL-1β levels were substantially decreased in both serum and diencephalon of NLRP3 knockout mice, while IL-6 levels were not significantly altered.
Inferred Conclusions
- LPS-induced fatigue is dependent on IL-1β signaling rather than other inflammatory cytokines.
- The NLRP3/caspase-1 pathway plays a causative role in the development of fatigue behaviors in this acute stress model.
- Inhibiting NLRP3 inflammasome activation may reverse or prevent fatigue symptoms.
Remaining Questions
- Does NLRP3 inflammasome activation occur in chronic or post-exertional fatigue, or only in acute immune challenge?
- How do findings in this acute mouse model relate to the pathophysiology of naturally-acquired, chronic ME/CFS in humans?
What This Study Does Not Prove
This animal model study does not prove that NLRP3 activation causes fatigue in humans or in ME/CFS patients specifically. The acute LPS plus swim stress model does not replicate the chronic, post-exertional nature of ME/CFS, and findings in mice may not translate to human disease pathophysiology. Correlation between NLRP3 activation and fatigue behavior does not establish causation in natural disease states.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:PEM Not DefinedExploratory Only
Metadata
- DOI
- 10.1186/s12974-016-0539-1
- PMID
- 27048470
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →